| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 99 | 2024 | 1023 | 14.210 |
Why?
|
| Neoplasm Recurrence, Local | 26 | 2024 | 249 | 5.200 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2024 | 60 | 2.910 |
Why?
|
| Female | 125 | 2024 | 12838 | 2.910 |
Why?
|
| Antineoplastic Agents, Hormonal | 9 | 2023 | 65 | 2.830 |
Why?
|
| Humans | 132 | 2024 | 18058 | 2.490 |
Why?
|
| Prospective Studies | 38 | 2024 | 1294 | 2.430 |
Why?
|
| Survivors | 20 | 2017 | 157 | 2.410 |
Why?
|
| Middle Aged | 90 | 2024 | 8073 | 2.350 |
Why?
|
| Aged | 76 | 2024 | 6258 | 2.300 |
Why?
|
| Aromatase Inhibitors | 6 | 2023 | 34 | 2.000 |
Why?
|
| Cardiovascular Diseases | 7 | 2024 | 613 | 1.880 |
Why?
|
| Cancer Survivors | 7 | 2024 | 88 | 1.860 |
Why?
|
| Osteoporosis | 4 | 2020 | 87 | 1.850 |
Why?
|
| Heart Failure | 4 | 2024 | 391 | 1.800 |
Why?
|
| Tamoxifen | 6 | 2023 | 60 | 1.790 |
Why?
|
| Obesity | 14 | 2017 | 839 | 1.650 |
Why?
|
| Adult | 61 | 2024 | 7696 | 1.630 |
Why?
|
| Lymphedema | 4 | 2012 | 8 | 1.620 |
Why?
|
| Neoplasm Staging | 26 | 2021 | 330 | 1.600 |
Why?
|
| Body Mass Index | 16 | 2017 | 961 | 1.520 |
Why?
|
| Prognosis | 27 | 2023 | 619 | 1.500 |
Why?
|
| California | 38 | 2020 | 2327 | 1.470 |
Why?
|
| Proportional Hazards Models | 27 | 2023 | 745 | 1.440 |
Why?
|
| Diet | 10 | 2024 | 359 | 1.380 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2020 | 10 | 1.340 |
Why?
|
| Risk Factors | 39 | 2023 | 3394 | 1.270 |
Why?
|
| Cohort Studies | 32 | 2024 | 2631 | 1.170 |
Why?
|
| Quality of Life | 11 | 2019 | 509 | 1.160 |
Why?
|
| Leukemia | 3 | 2022 | 9 | 1.150 |
Why?
|
| Isothiocyanates | 3 | 2024 | 8 | 1.060 |
Why?
|
| Diagnostic Imaging | 3 | 2020 | 43 | 1.020 |
Why?
|
| Ethnic Groups | 10 | 2019 | 504 | 1.020 |
Why?
|
| Mitomycin | 1 | 2024 | 4 | 0.980 |
Why?
|
| BCG Vaccine | 1 | 2024 | 6 | 0.980 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 1956 | 0.940 |
Why?
|
| Exercise | 9 | 2020 | 478 | 0.940 |
Why?
|
| Follow-Up Studies | 18 | 2024 | 1255 | 0.920 |
Why?
|
| Surveys and Questionnaires | 15 | 2019 | 1346 | 0.910 |
Why?
|
| Bone Density | 3 | 2020 | 98 | 0.910 |
Why?
|
| Breast Feeding | 3 | 2015 | 134 | 0.900 |
Why?
|
| Young Adult | 20 | 2024 | 2479 | 0.880 |
Why?
|
| Life Style | 12 | 2023 | 329 | 0.870 |
Why?
|
| Alcohol Drinking | 5 | 2019 | 375 | 0.860 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2015 | 55 | 0.860 |
Why?
|
| Survival Analysis | 14 | 2021 | 225 | 0.840 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2022 | 32 | 0.840 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2022 | 21 | 0.830 |
Why?
|
| Hallucinogens | 1 | 2022 | 23 | 0.830 |
Why?
|
| Biomarkers | 3 | 2020 | 306 | 0.820 |
Why?
|
| Fractures, Bone | 2 | 2020 | 91 | 0.800 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 57 | 0.780 |
Why?
|
| Receptors, Progesterone | 8 | 2018 | 51 | 0.780 |
Why?
|
| Osteoporotic Fractures | 1 | 2021 | 41 | 0.780 |
Why?
|
| Receptors, Estrogen | 7 | 2018 | 56 | 0.770 |
Why?
|
| Cannabis | 1 | 2022 | 73 | 0.750 |
Why?
|
| Social Support | 9 | 2021 | 211 | 0.750 |
Why?
|
| Hispanic Americans | 5 | 2017 | 431 | 0.740 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2016 | 57 | 0.740 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2018 | 552 | 0.730 |
Why?
|
| Risk Assessment | 12 | 2020 | 1137 | 0.710 |
Why?
|
| Male | 24 | 2024 | 10173 | 0.700 |
Why?
|
| Biomarkers, Tumor | 8 | 2018 | 144 | 0.680 |
Why?
|
| Dietary Supplements | 6 | 2016 | 91 | 0.680 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2012 | 393 | 0.680 |
Why?
|
| Diphosphonates | 2 | 2017 | 64 | 0.660 |
Why?
|
| Child | 13 | 2024 | 2519 | 0.640 |
Why?
|
| Continental Population Groups | 6 | 2018 | 317 | 0.630 |
Why?
|
| Neoplasm Invasiveness | 6 | 2024 | 83 | 0.610 |
Why?
|
| African Americans | 4 | 2016 | 485 | 0.590 |
Why?
|
| Bone Diseases | 1 | 2016 | 2 | 0.580 |
Why?
|
| Bone Remodeling | 1 | 2016 | 5 | 0.580 |
Why?
|
| Estrogen Receptor alpha | 3 | 2015 | 27 | 0.570 |
Why?
|
| Odds Ratio | 6 | 2020 | 692 | 0.570 |
Why?
|
| Adolescent | 17 | 2024 | 3714 | 0.570 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2016 | 4 | 0.570 |
Why?
|
| Adiposity | 3 | 2017 | 66 | 0.570 |
Why?
|
| European Continental Ancestry Group | 4 | 2016 | 559 | 0.550 |
Why?
|
| Lymph Nodes | 1 | 2016 | 17 | 0.540 |
Why?
|
| Paroxetine | 1 | 2015 | 23 | 0.540 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 31 | 0.540 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2015 | 28 | 0.530 |
Why?
|
| Electronic Health Records | 4 | 2016 | 734 | 0.530 |
Why?
|
| Vitamins | 3 | 2016 | 66 | 0.530 |
Why?
|
| Thinness | 2 | 2013 | 29 | 0.520 |
Why?
|
| Pathology Department, Hospital | 1 | 2015 | 3 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 49 | 0.520 |
Why?
|
| Case-Control Studies | 11 | 2020 | 1164 | 0.500 |
Why?
|
| Postmenopause | 5 | 2017 | 266 | 0.500 |
Why?
|
| Feeding Behavior | 4 | 2021 | 165 | 0.490 |
Why?
|
| Retrospective Studies | 11 | 2023 | 2498 | 0.480 |
Why?
|
| Body Weight | 4 | 2023 | 216 | 0.480 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 205 | 0.460 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 202 | 0.430 |
Why?
|
| Research Design | 1 | 2015 | 393 | 0.430 |
Why?
|
| Ontario | 3 | 2022 | 15 | 0.430 |
Why?
|
| United States | 12 | 2020 | 4119 | 0.430 |
Why?
|
| Residence Characteristics | 7 | 2023 | 248 | 0.420 |
Why?
|
| Treatment Outcome | 7 | 2024 | 1259 | 0.420 |
Why?
|
| Registries | 8 | 2016 | 486 | 0.410 |
Why?
|
| Survival Rate | 11 | 2017 | 266 | 0.410 |
Why?
|
| Communication | 1 | 2013 | 205 | 0.400 |
Why?
|
| Diet Surveys | 2 | 2010 | 57 | 0.400 |
Why?
|
| Colorectal Neoplasms | 4 | 2021 | 643 | 0.400 |
Why?
|
| Population Surveillance | 3 | 2016 | 270 | 0.390 |
Why?
|
| Clinical Competence | 1 | 2011 | 109 | 0.390 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2018 | 70 | 0.380 |
Why?
|
| Depression | 1 | 2015 | 512 | 0.380 |
Why?
|
| Time Factors | 8 | 2012 | 1114 | 0.380 |
Why?
|
| Socioeconomic Factors | 8 | 2018 | 667 | 0.370 |
Why?
|
| Receptor, ErbB-2 | 6 | 2024 | 47 | 0.370 |
Why?
|
| Self Report | 4 | 2016 | 252 | 0.370 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 177 | 0.360 |
Why?
|
| Age Factors | 7 | 2017 | 945 | 0.360 |
Why?
|
| Cystectomy | 2 | 2019 | 8 | 0.350 |
Why?
|
| China | 7 | 2016 | 126 | 0.350 |
Why?
|
| Prevalence | 4 | 2021 | 892 | 0.350 |
Why?
|
| Brassicaceae | 2 | 2023 | 7 | 0.340 |
Why?
|
| Sarcopenia | 2 | 2020 | 11 | 0.340 |
Why?
|
| Motor Activity | 5 | 2011 | 208 | 0.340 |
Why?
|
| Incidence | 6 | 2020 | 1297 | 0.340 |
Why?
|
| Hypertension | 2 | 2023 | 489 | 0.320 |
Why?
|
| Decision Making | 3 | 2019 | 204 | 0.320 |
Why?
|
| Mothers | 1 | 2009 | 110 | 0.320 |
Why?
|
| Vehicle Emissions | 1 | 2018 | 21 | 0.320 |
Why?
|
| Radiation Dosage | 2 | 2019 | 16 | 0.310 |
Why?
|
| Radiography | 3 | 2023 | 39 | 0.310 |
Why?
|
| Logistic Models | 6 | 2017 | 953 | 0.310 |
Why?
|
| Pregnancy | 3 | 2022 | 1484 | 0.310 |
Why?
|
| Air Pollutants | 1 | 2018 | 48 | 0.310 |
Why?
|
| Air Pollution | 1 | 2018 | 40 | 0.300 |
Why?
|
| Child, Preschool | 6 | 2020 | 1428 | 0.300 |
Why?
|
| Body Composition | 3 | 2021 | 80 | 0.300 |
Why?
|
| Ibuprofen | 1 | 2007 | 9 | 0.300 |
Why?
|
| Infant | 6 | 2023 | 1212 | 0.300 |
Why?
|
| Menarche | 1 | 2017 | 30 | 0.300 |
Why?
|
| Child Health | 1 | 2017 | 30 | 0.290 |
Why?
|
| Weight Gain | 3 | 2016 | 180 | 0.290 |
Why?
|
| Developmental Disabilities | 1 | 2017 | 48 | 0.290 |
Why?
|
| Smoking | 3 | 2022 | 465 | 0.290 |
Why?
|
| Maternal Welfare | 1 | 2006 | 15 | 0.290 |
Why?
|
| Breast | 1 | 2017 | 85 | 0.290 |
Why?
|
| Perinatal Care | 1 | 2006 | 12 | 0.290 |
Why?
|
| Aspirin | 1 | 2007 | 67 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 68 | 0.280 |
Why?
|
| Dietary Fats | 2 | 2019 | 90 | 0.280 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2024 | 31 | 0.270 |
Why?
|
| Mammography | 1 | 2017 | 173 | 0.270 |
Why?
|
| Confidence Intervals | 5 | 2021 | 249 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 118 | 0.260 |
Why?
|
| Leukemia, Myeloid | 1 | 2004 | 1 | 0.250 |
Why?
|
| Databases, Factual | 2 | 2019 | 330 | 0.250 |
Why?
|
| Mastectomy | 2 | 2017 | 36 | 0.250 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2006 | 144 | 0.250 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 595 | 0.250 |
Why?
|
| Vegetables | 4 | 2023 | 80 | 0.250 |
Why?
|
| Autism Spectrum Disorder | 1 | 2017 | 155 | 0.250 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2024 | 8 | 0.250 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 318 | 0.250 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 9 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 1 | 2024 | 15 | 0.240 |
Why?
|
| Comorbidity | 8 | 2020 | 618 | 0.240 |
Why?
|
| Down Syndrome | 1 | 2023 | 4 | 0.230 |
Why?
|
| Radiation Exposure | 1 | 2023 | 3 | 0.230 |
Why?
|
| Aging | 1 | 2004 | 159 | 0.220 |
Why?
|
| Complementary Therapies | 2 | 2016 | 52 | 0.220 |
Why?
|
| Trastuzumab | 1 | 2022 | 17 | 0.210 |
Why?
|
| Anthracyclines | 1 | 2022 | 16 | 0.210 |
Why?
|
| Weight Loss | 2 | 2016 | 296 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 705 | 0.210 |
Why?
|
| Premature Birth | 1 | 2024 | 135 | 0.210 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 147 | 0.210 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 47 | 0.210 |
Why?
|
| Interviews as Topic | 3 | 2012 | 327 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 103 | 0.200 |
Why?
|
| Lymphatic Metastasis | 3 | 2010 | 29 | 0.200 |
Why?
|
| Diet, Vegetarian | 1 | 2021 | 12 | 0.200 |
Why?
|
| Delivery of Health Care | 3 | 2020 | 445 | 0.200 |
Why?
|
| Premenopause | 3 | 2017 | 27 | 0.200 |
Why?
|
| Stroke Volume | 1 | 2022 | 95 | 0.200 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 193 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 407 | 0.200 |
Why?
|
| Capillary Permeability | 1 | 2001 | 1 | 0.200 |
Why?
|
| Mycoplasma Infections | 1 | 2001 | 1 | 0.200 |
Why?
|
| Substance P | 1 | 2001 | 1 | 0.200 |
Why?
|
| Trachea | 1 | 2001 | 2 | 0.200 |
Why?
|
| Albuterol | 1 | 2001 | 4 | 0.200 |
Why?
|
| Drug Hypersensitivity | 1 | 2001 | 10 | 0.190 |
Why?
|
| Soy Foods | 2 | 2012 | 10 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 1309 | 0.190 |
Why?
|
| Obesity, Morbid | 2 | 2013 | 121 | 0.190 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 24 | 0.190 |
Why?
|
| Colectomy | 1 | 2020 | 27 | 0.190 |
Why?
|
| Disease Progression | 2 | 2019 | 255 | 0.190 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 32 | 0.190 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 43 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2016 | 526 | 0.180 |
Why?
|
| Bone and Bones | 1 | 2020 | 10 | 0.180 |
Why?
|
| Body Size | 2 | 2017 | 31 | 0.180 |
Why?
|
| Fluoroscopy | 1 | 2019 | 2 | 0.180 |
Why?
|
| Radiometry | 1 | 2019 | 2 | 0.180 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 4 | 0.180 |
Why?
|
| Urinary Diversion | 1 | 2019 | 3 | 0.180 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 3 | 0.180 |
Why?
|
| Dietary Fiber | 1 | 2019 | 59 | 0.170 |
Why?
|
| Risk | 4 | 2017 | 552 | 0.170 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 48 | 0.170 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 155 | 0.170 |
Why?
|
| Asian Americans | 3 | 2016 | 184 | 0.170 |
Why?
|
| Gestational Age | 1 | 2019 | 119 | 0.170 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 57 | 0.170 |
Why?
|
| Neoplasms | 2 | 2015 | 464 | 0.160 |
Why?
|
| Patient Compliance | 2 | 2011 | 303 | 0.160 |
Why?
|
| Health Behavior | 4 | 2019 | 379 | 0.160 |
Why?
|
| Infant, Newborn | 3 | 2024 | 852 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 454 | 0.150 |
Why?
|
| Body Weights and Measures | 2 | 2017 | 13 | 0.150 |
Why?
|
| Prenatal Care | 1 | 2019 | 136 | 0.150 |
Why?
|
| Bone Neoplasms | 2 | 2016 | 8 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2017 | 154 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2017 | 10 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 3 | 0.150 |
Why?
|
| Bridged-Ring Compounds | 1 | 2016 | 4 | 0.140 |
Why?
|
| Taxoids | 1 | 2016 | 8 | 0.140 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 394 | 0.140 |
Why?
|
| Abdominal Fat | 1 | 2016 | 15 | 0.140 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 59 | 0.140 |
Why?
|
| Metabolic Equivalent | 1 | 2016 | 8 | 0.140 |
Why?
|
| Age of Onset | 1 | 2016 | 82 | 0.140 |
Why?
|
| Social Networking | 2 | 2013 | 20 | 0.140 |
Why?
|
| Overweight | 3 | 2017 | 272 | 0.140 |
Why?
|
| Vitamin D | 1 | 2017 | 78 | 0.140 |
Why?
|
| Algorithms | 2 | 2015 | 235 | 0.140 |
Why?
|
| Chi-Square Distribution | 3 | 2011 | 160 | 0.140 |
Why?
|
| Informed Consent | 1 | 2016 | 21 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2016 | 81 | 0.140 |
Why?
|
| Social Isolation | 1 | 2016 | 16 | 0.140 |
Why?
|
| Linear Models | 3 | 2012 | 240 | 0.140 |
Why?
|
| Health Resources | 1 | 2015 | 36 | 0.130 |
Why?
|
| Exome | 1 | 2015 | 25 | 0.130 |
Why?
|
| DNA | 1 | 2015 | 25 | 0.130 |
Why?
|
| Cell Proliferation | 1 | 2015 | 19 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 38 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2018 | 255 | 0.130 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 42 | 0.130 |
Why?
|
| Recreation | 1 | 2015 | 37 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 316 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 5 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 127 | 0.120 |
Why?
|
| Minerals | 1 | 2014 | 9 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 350 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 34 | 0.120 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2014 | 24 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 205 | 0.120 |
Why?
|
| Dairy Products | 1 | 2013 | 20 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 2 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 20 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2013 | 15 | 0.110 |
Why?
|
| Estrogens | 1 | 2013 | 73 | 0.110 |
Why?
|
| Data Mining | 1 | 2012 | 21 | 0.110 |
Why?
|
| Recurrence | 4 | 2014 | 186 | 0.110 |
Why?
|
| Employment | 1 | 2012 | 50 | 0.100 |
Why?
|
| Age Distribution | 1 | 2012 | 257 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 114 | 0.100 |
Why?
|
| Physicians | 1 | 2013 | 143 | 0.100 |
Why?
|
| Natural Language Processing | 1 | 2012 | 53 | 0.100 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2011 | 97 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2011 | 319 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2011 | 70 | 0.100 |
Why?
|
| Antioxidants | 3 | 2016 | 39 | 0.100 |
Why?
|
| Diet Records | 1 | 2010 | 32 | 0.090 |
Why?
|
| Health Surveys | 1 | 2011 | 266 | 0.090 |
Why?
|
| Demography | 1 | 2010 | 106 | 0.090 |
Why?
|
| Folic Acid | 1 | 2010 | 35 | 0.090 |
Why?
|
| Energy Intake | 1 | 2010 | 100 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2010 | 41 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2011 | 178 | 0.090 |
Why?
|
| Educational Status | 1 | 2010 | 205 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 82 | 0.090 |
Why?
|
| Internet | 1 | 2011 | 247 | 0.090 |
Why?
|
| Cause of Death | 3 | 2017 | 181 | 0.090 |
Why?
|
| Nutrition Assessment | 1 | 2009 | 27 | 0.090 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 56 | 0.090 |
Why?
|
| Nutrition Surveys | 1 | 2009 | 65 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 5 | 0.090 |
Why?
|
| Isoflavones | 1 | 2009 | 14 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 14 | 0.080 |
Why?
|
| Geographic Mapping | 1 | 2018 | 4 | 0.080 |
Why?
|
| Geography | 1 | 2008 | 38 | 0.080 |
Why?
|
| Cities | 1 | 2018 | 29 | 0.080 |
Why?
|
| Fruit | 2 | 2019 | 72 | 0.080 |
Why?
|
| SEER Program | 2 | 2020 | 100 | 0.080 |
Why?
|
| Public Health Surveillance | 2 | 2018 | 45 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2007 | 12 | 0.070 |
Why?
|
| Disease Management | 2 | 2018 | 143 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2007 | 51 | 0.070 |
Why?
|
| Emotions | 2 | 2021 | 33 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 6 | 0.070 |
Why?
|
| Protective Factors | 2 | 2016 | 32 | 0.070 |
Why?
|
| Mental Health | 1 | 2017 | 166 | 0.070 |
Why?
|
| Bottle Feeding | 1 | 2005 | 8 | 0.070 |
Why?
|
| Infant Food | 1 | 2005 | 8 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2006 | 157 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2004 | 86 | 0.060 |
Why?
|
| Income | 1 | 2004 | 95 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 2 | 0.060 |
Why?
|
| Anthropometry | 1 | 2004 | 63 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 20 | 0.060 |
Why?
|
| Hormones | 1 | 2024 | 16 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 27 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2005 | 108 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2004 | 68 | 0.060 |
Why?
|
| Mortality | 2 | 2016 | 121 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2014 | 79 | 0.060 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2024 | 56 | 0.060 |
Why?
|
| Cystatin C | 1 | 2023 | 15 | 0.060 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2023 | 24 | 0.060 |
Why?
|
| Albumins | 1 | 2023 | 6 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2004 | 184 | 0.060 |
Why?
|
| Guideline Adherence | 2 | 2016 | 160 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 248 | 0.050 |
Why?
|
| Utah | 2 | 2014 | 31 | 0.050 |
Why?
|
| Evans Blue | 1 | 2001 | 1 | 0.050 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2001 | 1 | 0.050 |
Why?
|
| Indoles | 1 | 2001 | 1 | 0.050 |
Why?
|
| Organometallic Compounds | 1 | 2001 | 1 | 0.050 |
Why?
|
| Platelet Activating Factor | 1 | 2001 | 1 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2001 | 1 | 0.050 |
Why?
|
| Salmeterol Xinafoate | 1 | 2001 | 2 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2001 | 3 | 0.050 |
Why?
|
| Species Specificity | 1 | 2001 | 5 | 0.050 |
Why?
|
| Rats, Inbred F344 | 1 | 2001 | 5 | 0.050 |
Why?
|
| Serotonin | 1 | 2001 | 6 | 0.050 |
Why?
|
| Narration | 1 | 2021 | 11 | 0.050 |
Why?
|
| Rats | 1 | 2001 | 28 | 0.050 |
Why?
|
| Organ Size | 1 | 2001 | 16 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2001 | 14 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 4 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2020 | 18 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 129 | 0.050 |
Why?
|
| Survivorship | 1 | 2020 | 9 | 0.050 |
Why?
|
| Morbidity | 1 | 2020 | 62 | 0.050 |
Why?
|
| Animals | 1 | 2001 | 250 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2019 | 11 | 0.040 |
Why?
|
| Barium | 1 | 2019 | 1 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 16 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 6 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2011 | 162 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 5 | 0.040 |
Why?
|
| Thorax | 1 | 2019 | 5 | 0.040 |
Why?
|
| Spine | 1 | 2019 | 7 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2010 | 20 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 182 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 267 | 0.040 |
Why?
|
| Head | 1 | 2019 | 8 | 0.040 |
Why?
|
| Abdomen | 1 | 2019 | 20 | 0.040 |
Why?
|
| Hospitals | 1 | 2020 | 79 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2019 | 36 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2019 | 84 | 0.040 |
Why?
|
| Minority Groups | 1 | 2019 | 103 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2020 | 161 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 233 | 0.040 |
Why?
|
| Patients | 1 | 2018 | 39 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2001 | 462 | 0.040 |
Why?
|
| Transcriptome | 1 | 2017 | 22 | 0.040 |
Why?
|
| Fast Foods | 1 | 2017 | 12 | 0.040 |
Why?
|
| Health Personnel | 1 | 2018 | 122 | 0.040 |
Why?
|
| Fish Oils | 1 | 2016 | 2 | 0.040 |
Why?
|
| Melatonin | 1 | 2016 | 3 | 0.040 |
Why?
|
| Plant Preparations | 1 | 2016 | 6 | 0.040 |
Why?
|
| Therapeutic Touch | 1 | 2016 | 3 | 0.040 |
Why?
|
| Glucosamine | 1 | 2016 | 3 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 29 | 0.040 |
Why?
|
| Mind-Body Therapies | 1 | 2016 | 10 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 69 | 0.040 |
Why?
|
| Arizona | 1 | 2016 | 6 | 0.040 |
Why?
|
| Massage | 1 | 2016 | 18 | 0.040 |
Why?
|
| Causality | 1 | 2016 | 43 | 0.040 |
Why?
|
| Yoga | 1 | 2016 | 26 | 0.040 |
Why?
|
| Meditation | 1 | 2016 | 20 | 0.040 |
Why?
|
| Acupuncture Therapy | 1 | 2016 | 34 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 2016 | 19 | 0.030 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2015 | 1 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2015 | 2 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2015 | 40 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 346 | 0.030 |
Why?
|
| Environment | 1 | 2015 | 52 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 634 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 132 | 0.030 |
Why?
|
| Genomics | 1 | 2015 | 65 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 208 | 0.030 |
Why?
|
| Stroke | 1 | 2016 | 306 | 0.030 |
Why?
|
| Viscera | 1 | 2013 | 1 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 32 | 0.030 |
Why?
|
| Systematized Nomenclature of Medicine | 1 | 2012 | 5 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2012 | 53 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2012 | 55 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2012 | 97 | 0.030 |
Why?
|
| Vitamin E | 1 | 2011 | 20 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 2011 | 18 | 0.030 |
Why?
|
| Carotenoids | 1 | 2011 | 30 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2012 | 89 | 0.030 |
Why?
|
| Caregivers | 1 | 2012 | 125 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 18 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 328 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 299 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 44 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1988 | 1 | 0.020 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1988 | 1 | 0.020 |
Why?
|
| Sarcoma, Ewing | 1 | 1988 | 2 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 1988 | 23 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 92 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2009 | 248 | 0.020 |
Why?
|
| Choline O-Acetyltransferase | 1 | 1988 | 1 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 1988 | 1 | 0.010 |
Why?
|